ALNY_JPM26_PRESENTATION_01.12.2026.pdf

1、 2026 Alnylam Pharmaceuticals,Inc.Yvonne Greenstreet,M.D.Chief Executive OfficerJanuary 12,2026Accelerating Innovation and Scaling Impact to Transform Human Health44thAnnual J.P.Morgan Healthcare Conference2This presentation contains forward-looking statements within the meaning of Section 27A of th

2、e Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,including,without limitation,statements regarding our 2026 financial guidance,our aspirational five-year objectives,our ability to continue to innovate,our ability to achieve durable growth,and market value projections.S

3、uch statements incorporate the additional forward-looking statements about potential timing and success of(1)clinical and regulatory advancement of product candidates and(2)potential commercialization and financial contribution from those candidates.Each forward-looking statement contained in this d

4、eck is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.Applicable risks and uncertainties include our potential inability to grow revenue from currently marketed products and to successfully advance,and generat

5、e revenue from,product candidates,each of which may be negatively impacted by competition from products marketed by other companies and product candidates developed by other companies that successfully reach the market;negative decisions by regulatory authorities,including adverse regulatory actions

6、 or dosing and labeling determinations;challenges enrolling clinical trials rapidly and successfully;healthcare providers,patients,and regulators not assessing our products to have a positive benefit-risk profile;the sizes of patient populations we seek to address being smaller than stated or implie